Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death not only in Japan but worldwide. Clinical Practice Guidelines for HCC were published in 2001 by the European Society of Study of the Liver (EASL) and in 2005 by the American Association for the Study of Liver Disease (AASLD). However, these guidelines have proven to be somewhat unsuitable for Japanese patients. In 2005, supported by the Japanese Ministry of Health, Labor and Welfare, Evidence-Based Clinical Practice Guidelines for HCC were compiled. Based on ‘evidence-based’ guidelines and the consensus of an expert panel on HCC, the Japan Society of Hepatology (JSH) published the Consensus-Based Clinical Practice Manual in 2007. In this article, the content of this manual, especially issues on surveillance, diagnosis, staging, and treatment, is summarized.

Keywords:
Hepatocellular carcinoma, staging, surveillance, diagnostic algorithm, treatment algorithm, Clinical practice guidelines, manual, Evidence-based clinical practice guideline, Consensus-based clinical practice manual
1.
Bruix J, Sherman M, Llovet JM, et al: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421–430.
2.
Bruix J, Sherman M, AASLD practice guideline: management of hepatocellular carcinoma. Hepatology 2005;42:1208–1236.
3.
Group formed to establish ‘Guidelines for evidence-based clinical practice for the treatment of liver cancer’. Clinical Practice Guidelines for Hepatocellular Carcinoma (in Japanese). Tokyo, Kanehara, 2005.
4.
Makuuchi M, Kokudo N: Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 2006;12:828–829.
5.
Kokudo N, Sasaki Y, Nakayama T, et al: Dissemination of evidence-based clinical practice guidelines for hepatocellular carcinoma among Japanese hepatologists, liver surgeons and primary care physicians. Gut 2007;56:1020–1021.
6.
Expert Panel of Japan Society of Hepatology: Clinical Practice Manual for Hepatocellular Carcinoma (in Japanese). Tokyo, Igaku-Shoin, 2007.
7.
Chalasani N, Horlander JC Sr, Said A, et al: Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 1998;94:2988–2993.
8.
Ueda K, Matsui O, Kawamori Y, et al: Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology 1998;206:161–166.
9.
Shapiro RS, Katz R, Mendelson DS, et al: Detection of hepatocellular carcinoma in cirrhotic patients: sensitivity of CT and ultrasonography. J Ultrasound Med 1996;15:497–502.
10.
Lim JH, Kim CK, Lee WJ, et al: Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR Am J Roentgenol 2000;175:693–698.
11.
Peterson MS, Baron RL, Marsh JW, et al: Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: epidemiology and CT-based tumor detection rate in 430 cases with surgical pathologic correlation. Radiology 2000;217:743–749.
12.
Rode A, Bancel B, Douek P, et al: Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted livers. J Comput Assist Tomogr 2001;25:327–336.
13.
Kubota K, Hisa N, Nishikawa T, et al: Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemolipiodolization: comparison of lipiodol-CT, power Doppler sonography, and dynamic MRI. Abdom Imaging 2001;26:184–190.
14.
Nakayama A, Imamura H, Matsuyama Y, et al: Value of lipiodol computed tomography and digital subtraction angiography in the era of helical biphasic computed tomography as preoperative assessment of hepatocellular carcinoma. Ann Surg 2001;234:56–62.
15.
Tanimoto A, Wakabayashi G, Shinmoto H, et al: Superparamagnetic iron oxide-enhanced MR imaging for focal hepatic lesions: a comparison with CT during arteriography plus CT during hepatic arteriography. J Gastroenterol 2005;40:371–380.
16.
Sakamoto M, Hirohashi S, Shimosato Y: Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991;22:172–178.
17.
Kojiro M: Pathology of hepatocellular carcinoma; in Okuda K, Tabor E (eds): Liver Cancer. New York, Churchill-Livingstone, 1997, pp 165–187.
18.
Sakamoto M, Hirohashi S: Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jpn J Clin Oncol 1999;28:604–608.
19.
Hayashi M, Matsui O, Ueda K, et al: Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002;225:143–149.
20.
Tajima T, Honda H, Tagushi K, et al: Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. AJR 2002;178:885–897.
21.
Kudo M: Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesions. Semin Liver Dis 1999;19:297–309.
22.
Kudo M: Contrast Harmonic Imaging in the Diagnosis and Treatment of Hepatic Tumors. Tokyo, Springer, 2003.
23.
Wen YL, Kudo M, Zheng RQ, et al: Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio. AJR 2004;182:1019–1026.
24.
Imai Y, Murakami T, Yoshida S, et al: Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000;32:205–212.
25.
Asahina Y, Izumi N, Uchihara M, et al: Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocellular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography. Hepatol Res 2003;27:196–204.
26.
Liver Cancer Study Group of Japan: General Rules for the Clinical and Pathological Study of Primary Liver Cancer, English ed 2. Tokyo, Kanehara, 2003.
27.
Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985;56:918–928.
28.
Bruix J, Sherman M, Llovet JM, et al: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421–430.
29.
Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329–338.
30.
The Cancer of the Liver Italian Program (CLIP) Investigators: Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:840–845.
31.
Kudo M, Chung H, Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging score (JIS score). J Gastroenterol 2003;38:207–215.
32.
Kudo M, Chung H, Haji S, et al: Validation of a new prognostic staging system for hepatocellular carcinoma, the JIS score as compared with CLIP score. Hepatology, 2004;40:1396–1405.
33.
Tateishi R, Yoshida H, Shiina S, et al: Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005;54:419–425.
34.
Ikai I, Takayasu K, Omata M, et al: A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol 2006;41:884–892.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.